Top Page
Swiss Re AG
(SREN)
Swiss Re AG (SREN) vs. iShares MSCI Switzerland ETF (EWL)
Swiss Re AG Business Overview & Revenue Model
Swiss Re AG Earnings Call Summary
Swiss Re AG Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.96B | 8.72B | 49.73B | 46.04B | 46.74B | 43.34B |
| Gross Profit | 21.96B | 12.37B | 49.46B | 46.04B | 46.74B | 43.34B |
| EBITDA | 0.00 | 4.27B | -23.00M | 1.64B | -573.00M | 115.00M |
| Net Income | 2.38B | 3.24B | 3.21B | 472.00M | 1.44B | -878.00M |
Balance Sheet | ||||||
| Total Assets | 135.34B | 127.23B | 179.58B | 170.68B | 181.57B | 182.62B |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 88.64B | 88.38B | 85.61B | 4.15B | 4.70B |
| Total Debt | 8.47B | 7.26B | 9.82B | 11.04B | 11.19B | 11.74B |
| Total Liabilities | 111.27B | 103.99B | 163.21B | 157.87B | 10.32B | 11.58B |
| Stockholders Equity | 23.93B | 23.11B | 16.15B | 12.70B | 23.57B | 27.14B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.13B | 4.09B | 2.93B | 4.10B | 5.39B |
| Operating Cash Flow | 0.00 | 3.13B | 4.09B | 2.93B | 4.10B | 5.39B |
| Investing Cash Flow | 0.00 | -407.00M | -362.00M | -2.34B | -2.14B | -7.72B |
| Financing Cash Flow | 0.00 | -2.97B | -3.22B | -1.24B | -2.10B | -2.50B |
Swiss Re AG Technical Analysis
Swiss Re AG Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $79.70B | 15.82 | 23.97% | 4.86% | -7.33% | 17.93% | |
73 Outperform | $40.74B | 13.72 | 17.22% | 3.92% | -4.94% | -5.71% | |
70 Outperform | €1.83B | 12.14 | 6.06% | 3.73% | -1.58% | 4.07% | |
68 Neutral | CHF9.10B | 20.76 | ― | 3.92% | -9.11% | 73.67% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
68 Neutral | $24.77B | 20.94 | 17.11% | 3.98% | -1.65% | 10.05% | |
59 Neutral | CHF10.64B | 19.44 | ― | 3.21% | -1.57% | 95.56% |
Swiss Re AG Corporate Events
Swiss Re’s latest sigma report highlights the transformative impact of the ‘Silver Economy’ on the life insurance industry, driven by an aging population, declining birth rates, and wealth concentration among seniors. By 2050, a significant portion of the population in industrialized countries will be over 65, necessitating a shift in life insurers’ focus from income replacement to wealth planning and personal care financing. This demographic shift presents opportunities for insurers to innovate in product design and delivery, addressing the needs of retirees who face the risk of outliving their savings. The report emphasizes the importance of developing new financial products, such as longevity risk distribution pools and cancer-specific insurance, to meet the evolving demands of an aging population, while also highlighting the growing pressure on long-term care services.
The most recent analyst rating on (CH:SREN) stock is a Hold with a CHF160.00 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
Swiss Re’s recent study highlights the potential impact of GLP-1 medications on reducing mortality rates in the USA and UK by 2045, assuming widespread use and lifestyle changes. The study emphasizes the importance of lifestyle modifications alongside medication use to achieve significant mortality reductions, with implications for insurers in risk assessment and benefit claims development.
The most recent analyst rating on (CH:SREN) stock is a Buy with a CHF158.00 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
Swiss Re emphasizes the importance of a holistic approach to maintaining resilience amid complex risks, highlighting the role of AI in improving risk assessment and underwriting quality. The company underscores the urgency of preventive measures against natural disasters and stresses the need for collaboration between public and private sectors to mitigate risks. Geopolitical uncertainties and fragmentation pose challenges to the re/insurance market, affecting risk assessment and causing volatility. Swiss Re views re/insurance as a stabilizing force during global upheavals, supporting economic recovery and resilience.
The most recent analyst rating on (CH:SREN) stock is a Buy with a CHF161.40 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
The Swiss Re Institute reports that the global property and casualty insurance market, valued at USD 2.4 trillion, is set to grow alongside global GDP over the next decade, driven by increasing natural disaster damages and economic factors. The market’s maturity is evident through the entry of smaller players and the adoption of alternative risk solutions, enhancing capacity and affordability. The industry is becoming more efficient with specialization and outsourced underwriting, while the use of alternative risk solutions helps manage rising risks, particularly in catastrophe-prone regions. Reinsurers play a critical role in maintaining stability and capacity, despite new dependencies on capital markets.
The most recent analyst rating on (CH:SREN) stock is a Buy with a CHF161.40 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
Swiss Re AG, headquartered in Zurich, Switzerland, is a leading global provider of reinsurance, insurance, and other insurance-based risk transfer solutions, known for its focus on making the world more resilient to risks such as natural catastrophes and climate change.
Swiss Re reported a profit of USD 2.6 billion for the first half of 2025, driven by strong underwriting margins and a solid investment performance. The company achieved a return on equity of 23.0%, with significant contributions from its Property & Casualty Reinsurance, Corporate Solutions, and Life & Health Reinsurance segments. Despite a challenging pricing environment, Swiss Re maintained robust contractual service margins and a strong capital position, with a Swiss Solvency Test ratio of 264%. The company’s strategic focus on disciplined underwriting and cost efficiency continues to support its financial targets amid geopolitical and macroeconomic uncertainties.
The most recent analyst rating on (CH:SREN) stock is a Hold with a CHF132.00 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
Swiss Re has updated its Life Guide to include guidance on assessing life insurance applicants using repurposed longevity drugs like metformin and rapamycin. This update aims to help underwriters make informed decisions in light of the uncertain long-term effects of these drugs, which are gaining popularity for their potential anti-aging benefits. The Life Guide, used by over 800 insurance companies globally, now also features improved tools for assessing chronic kidney disease and prostate cancer risks, reinforcing Swiss Re’s commitment to evidence-based underwriting in a changing health landscape.
The most recent analyst rating on (CH:SREN) stock is a Hold with a CHF132.00 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
Swiss Re Institute reports that insured losses from natural disasters in the first half of 2025 reached $80 billion, driven by record-breaking wildfires in California and severe thunderstorms in the USA. This figure is nearly double the ten-year average and suggests that total losses for the year could surpass the $150 billion forecast. The increase in losses is attributed to factors such as rising temperatures, more frequent droughts, and urban expansion into high-risk areas. The report underscores the importance of enhanced damage mitigation and adaptation measures to increase community resilience.
The most recent analyst rating on (CH:SREN) stock is a Hold with a CHF132.00 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.